Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Celltrion Inc (068270)
Celltrion Inc stock price live, this page displays KS 068270 stock exchange data. View the 068270 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Celltrion Inc real time stock price chart below.
What Is the Celltrion Inc Stock Price Today?
The Celltrion Inc stock price today is 160,200.
What Is the Stock Symbol for Celltrion Inc?
The stock symbol for Celltrion Inc is "068270."
What Stock Exchange Does Celltrion Inc Trade On?
Celltrion Inc is listed and trades on the Seoul stock exchange.
Is Celltrion Inc a Good Stock to Buy?
Determining whether Celltrion Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 068270 quote. (ISIN: KR7068270008)
What Is the Celltrion Inc Stock Price Today?
The Celltrion Inc stock price today is 160,200.
What Is the Stock Symbol for Celltrion Inc?
The stock symbol for Celltrion Inc is "068270."
What Stock Exchange Does Celltrion Inc Trade On?
Celltrion Inc is listed and trades on the Seoul stock exchange.
Is Celltrion Inc a Good Stock to Buy?
Determining whether Celltrion Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 068270 quote. (ISIN: KR7068270008)
Seoul
Currency in KRW
160,200
-2,100(-1.29%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
159,600
162,300
52 wk Range
150,400
211,000
068270 Scorecard
Full Analysis
Management has been aggressively buying back shares
068270 is included in our AI-picked strategies. See how they work
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
159,600162,300
52 wk Range
150,400211,000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.44%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.44%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
068270 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
214,742
Upside
+34.05%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Celltrion Inc Company Profile
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of various therapeutic proteins for the treatment of oncology diseases. It operates through Biopharmaceutical Medicines, Chemical Medicines, and Others segments. The company offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin’s lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. It is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. In addition, the company engages in the wholesale/retail of medicines. The company distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Compare 068270 to Peers and Sector
Metrics to compare | 068270 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship068270PeersSector | |
|---|---|---|---|---|
P/E Ratio | 70.5x | 27.1x | −0.5x | |
PEG Ratio | 62.85 | 0.07 | 0.00 | |
Price/Book | 2.1x | 1.6x | 2.6x | |
Price / LTM Sales | 9.8x | 1.9x | 3.0x | |
Upside (Analyst Target) | 36.3% | 18.3% | 51.5% | |
Fair Value Upside | Unlock | 12.2% | 9.4% | Unlock |
Analyst Ratings
19 Buy
2 Hold
1 Sell
Ratings:
22 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 214,742
(+34.05% Upside)
Earnings
Latest Release
May 09, 2025
EPS / Forecast
486.75 / 726.59
Revenue / Forecast
841.91B / 989.14B
People Also Watch
FAQ
What Is the Celltrion (068270) Stock Price Today?
The Celltrion stock price today is 160,200.00
What Stock Exchange Does Celltrion Trade On?
Celltrion is listed and trades on the Seoul Stock Exchange stock exchange.
What Is the Stock Symbol for Celltrion?
The stock symbol for Celltrion is "068270."
Does Celltrion Pay Dividends? What’s The Current Dividend Yield?
The Celltrion dividend yield is 0.44%.
What Is the Celltrion Market Cap?
As of today, Celltrion market cap is 35.89T.
What Is Celltrion's Earnings Per Share (TTM)?
The Celltrion EPS (TTM) is 2,292.63.
When Is the Next Celltrion Earnings Date?
Celltrion will release its next earnings report on Aug 08, 2025.
From a Technical Analysis Perspective, Is 068270 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Celltrion Stock Split?
Celltrion has split 18 times.
How Many Employees Does Celltrion Have?
Celltrion has 2391 employees.
What is the current trading status of Celltrion (068270)?
As of Jun 19, 2025, Celltrion (068270) is trading at a price of 160,200.00, with a previous close of 162,300.00. The stock has fluctuated within a day range of 159,600.00 to 162,300.00, while its 52-week range spans from 150,400.00 to 211,000.00.
What Is Celltrion (068270) Price Target According to Analysts?
The average 12-month price target for Celltrion is KRW214742.13287, with a high estimate of KRW250000 and a low estimate of KRW134615.38462. 19 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +34.05% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.